OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
27 mai 2021 12h00 HE
|
OSE Immunotherapeutics
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explore the strategy of...
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
26 mai 2021 01h30 HE
|
OSE Immunotherapeutics
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated...
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
20 mai 2021 01h30 HE
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is under collaborative development with Boehringer Ingelheim.Data indicate BI 765063 was well tolerated and showed...
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
18 mai 2021 01h30 HE
|
OSE Immunotherapeutics
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multi-epitopes.CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging...
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market
26 avr. 2021 12h00 HE
|
OSE Immunotherapeutics
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.OSE Immunotherapeutics to receive up to €315 million in potential...
OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
06 avr. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach...
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
01 avr. 2021 12h00 HE
|
OSE Immunotherapeutics
CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses.CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and...
OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
26 mars 2021 13h00 HE
|
OSE Immunotherapeutics
Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2...
OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
15 mars 2021 01h30 HE
|
OSE Immunotherapeutics
This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,...
OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting
11 mars 2021 12h00 HE
|
OSE Immunotherapeutics
CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 to...